<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525057</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0743</org_study_id>
    <secondary_id>NCI-2018-01848</secondary_id>
    <secondary_id>2004-0743</secondary_id>
    <nct_id>NCT00525057</nct_id>
  </id_info>
  <brief_title>Dalteparin in Preventing DVT in Participants With Cancer</brief_title>
  <official_title>DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood&#xD;
      clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots&#xD;
      and may prevent them from forming.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety of dalteparin as prophylaxis against deep venous thrombosis (DVT)&#xD;
      in orthopedic oncology patients.&#xD;
&#xD;
      II. To determine whether there are significantly increased bleeding complications at the&#xD;
      surgical site after major oncologic operations in the lower extremity.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive dalteparin subcutaneously (SC) once daily (QD) starting 12-24 hours&#xD;
      after surgery on post-operative day 1 until hospital discharge, about 7-10 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2006</start_date>
  <completion_date type="Actual">June 19, 2020</completion_date>
  <primary_completion_date type="Actual">June 19, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Post-operative Wound Complications</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Occurrence of Venous Thromboembolism</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-Operative Blood Transfusion</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>The volume of packed red blood cell transfusion in the post-operative period</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Bone Sarcoma</condition>
  <condition>Femur Fracture</condition>
  <condition>Lymphoma</condition>
  <condition>Metastatic Neoplasm</condition>
  <condition>Pathologic Fracture</condition>
  <condition>Plasma Cell Myeloma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (dalteparin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (dalteparin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  GROUP A&#xD;
&#xD;
          -  Metastatic disease, myeloma, lymphoma.&#xD;
&#xD;
          -  Pathologic fracture or impending pathologic fracture of the femur.&#xD;
&#xD;
          -  Intramedullary rod, plating, cementation, hip arthroplasty, or knee arthroplasty.&#xD;
&#xD;
          -  GROUP B&#xD;
&#xD;
          -  Primary sarcoma of bone or soft tissue of the lower extremity.&#xD;
&#xD;
          -  T2 tumor (&gt; 5 cm by &lt; 20 cm).&#xD;
&#xD;
          -  Radical resection of tumor, which may necessitate major bone or soft tissue&#xD;
             reconstruction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of DVT on pre-operative screening ultrasound study.&#xD;
&#xD;
          -  Massive tumor (&gt; 20 cm in greatest dimension).&#xD;
&#xD;
          -  Amputation of the affected leg as treatment of tumor.&#xD;
&#xD;
          -  Estimated blood loss &gt; 2 liters during surgery.&#xD;
&#xD;
          -  Surgical drain output &gt; 500 cc of bloody fluid during first 8 hours.&#xD;
&#xD;
          -  International normalized ratio (I.N.R.) &gt; 1.3 pre-operatively or &gt; 1.5&#xD;
             post-operatively.&#xD;
&#xD;
          -  Platelet count &lt; 100,000 either pre-operatively or post-operatively.&#xD;
&#xD;
          -  Indwelling post-operative epidural catheter for pain control.&#xD;
&#xD;
          -  History of underlying bleeding disorder, such as hemophilia.&#xD;
&#xD;
          -  History of adverse reaction to heparin such as heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Severe liver or renal insufficiency.&#xD;
&#xD;
          -  History of hypertensive or diabetic retinopathy.&#xD;
&#xD;
          -  History of gastro-intestinal bleeding within 12 months.&#xD;
&#xD;
          -  Treatment with warfarin, clopidogrel, aspirin, nonsteroidal antiinflammatory drugs&#xD;
             (NSAIDs), low molecular weight heparin (LMWH) or other anti-coagulants for conditions.&#xD;
&#xD;
          -  History of stroke.&#xD;
&#xD;
          -  Women of child bearing potential having a positive urine or serum pregnancy test&#xD;
             (human chorionic gonadotropin [hCG]) at the time of pre-operative evaluation (within 7&#xD;
             days of surgery).&#xD;
&#xD;
          -  Women who are breastfeeding.&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dL.&#xD;
&#xD;
          -  Platelet count &lt; 100,000/L.&#xD;
&#xD;
          -  Alanine aminotransferase &gt; 100 IU/L.&#xD;
&#xD;
          -  Aspartate aminotransferase &gt; 100 IU/L.&#xD;
&#xD;
          -  Direct bilirubin &gt; 0.5mg/dL.&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL.&#xD;
&#xD;
          -  Patients taking COX-2 inhibitors.&#xD;
&#xD;
          -  Patients who have fragmented mechanical heart valves.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Lin</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <results_first_submitted>December 8, 2020</results_first_submitted>
  <results_first_submitted_qc>December 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Fractures, Spontaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 19, 2009</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT00525057/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 2006 - December 2010</recruitment_details>
      <pre_assignment_details>A total of 65 participants enrolled into the trial. 15 participants did not meet entry criteria and were excluded.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interventional (Dalteparin, Metastatic)</title>
          <description>Received dalteparin 5000 units daily postop, patients with metastatic disease.</description>
        </group>
        <group group_id="P2">
          <title>Interventional (Dalteparin, Sarcoma)</title>
          <description>Received dalteparin 5000 units daily postop, patients with primary sarcomas.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interventional (Dalteparin, Metastatic)</title>
          <description>Received dalteparin 5000 units daily postop, patients with metastatic disease.</description>
        </group>
        <group group_id="B2">
          <title>Interventional (Dalteparin, Sarcoma)</title>
          <description>Received dalteparin 5000 units daily postop, patients with primary sarcomas.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Location</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Femur/Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibia/Calf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Popliteal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sarcoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Wide Excision Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segmental Reconstruction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Curettage, Internal Fixation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Post-operative Wound Complications</title>
        <description>Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.</description>
        <time_frame>4 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interventional (Dalteparin, Metastatic)</title>
            <description>Received dalteparin 5000 units daily postop, patients with metastatic disease.</description>
          </group>
          <group group_id="O2">
            <title>Interventional (Dalteparin, Sarcoma)</title>
            <description>Received dalteparin 5000 units daily postop, patients with primary sarcomas.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-operative Wound Complications</title>
          <description>Our primary outcome was the incidence of post-surgical complications, to include wound dehiscence, infection, and seroma.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wound Dehiscence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Occurrence of Venous Thromboembolism</title>
        <description>A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.</description>
        <time_frame>4 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interventional (Dalteparin, Metastatic)</title>
            <description>Received dalteparin 5000 units daily postop, patients with metastatic disease.</description>
          </group>
          <group group_id="O2">
            <title>Interventional (Dalteparin, Sarcoma)</title>
            <description>Received dalteparin 5000 units daily postop, patients with primary sarcomas.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Occurrence of Venous Thromboembolism</title>
          <description>A secondary outcome was the occurrence of venous thrombolembolism in the post-operative period, to include both deep venous thrombosis in the lower extremity as well as pulmonary embolism.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deep venous thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-Operative Blood Transfusion</title>
        <description>The volume of packed red blood cell transfusion in the post-operative period</description>
        <time_frame>4 weeks after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Interventional (Dalteparin, Metastatic)</title>
            <description>Received dalteparin 5000 units daily postop, patients with metastatic disease.</description>
          </group>
          <group group_id="O2">
            <title>Interventional (Dalteparin, Sarcoma)</title>
            <description>Received dalteparin 5000 units daily postop, patients with primary sarcomas.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Operative Blood Transfusion</title>
          <description>The volume of packed red blood cell transfusion in the post-operative period</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="0" upper_limit="685"/>
                    <measurement group_id="O2" value="271" lower_limit="0" upper_limit="2059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks after surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Interventional (Dalteparin, Metastatic)</title>
          <description>Received dalteparin 5000 units daily postop, patients with metastatic disease.</description>
        </group>
        <group group_id="E2">
          <title>Interventional (Dalteparin, Sarcoma)</title>
          <description>Received dalteparin 5000 units daily postop, patients with primary sarcomas.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Patrick Lin, MD/Professor, Orthopaedic Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 745-0088</phone>
      <email>plin@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

